PIM3
Serine/threonine-protein kinase pim-3
As of the edition of 20 October 2026, PIM3 (serine/threonine-protein kinase pim-3, UniProt Q86V86) has 4 drugs tested at it and 5 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q86V86
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Urinary and reproductive
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| LGH-447 | Went quiet | Phase 1 | none listed |
| ETH-155008 | Stopped | Phase 1 | none listed |
| SGI-1776 | Stopped | Phase 1 | none listed |
| AZD-1208 | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Novartis | Route A |
| Otsuka | Route A |
The other 2 companies at PIM3
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at PIM3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.